TECTONIC THERAPEUTIC, INC. Interest Expense on Debt
TECTONIC THERAPEUTIC, INC. (TECX) reported Interest Expense on Debt of $1.92 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpenseDebt · last filed 2024-03-14
- TECTONIC THERAPEUTIC, INC. interest expense, debt for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense, debt for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense, debt for the quarter ending 2023-06-30 was $1.37M, a 310.51% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense, debt for the quarter ending 2023-03-31 was $550.00K, a 80.92% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. interest expense, debt for fiscal 2023 was $1.92M, a 6.03% increase from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. interest expense, debt for fiscal 2022 was $1.81M, a 790.64% increase from fiscal 2021.
- TECTONIC THERAPEUTIC, INC. interest expense, debt for fiscal 2021 was $203.00K.
| Period end | Interest Expense, Debt 3 month | Interest Expense, Debt 6 month | Interest Expense, Debt 9 month | Interest Expense, Debt 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $1.37M derived: sum of 3 quarters · filed 2024-03-14 | $1.92M 10-K · filed 2024-03-14 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | $1.37M derived: sum of 2 quarters · filed 2023-11-09 | $1.92M 10-Q · filed 2023-11-09 | $2.44M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-06-30 | $1.37M 10-Q · filed 2023-08-10 | $1.92M 10-Q · filed 2023-08-10 | $2.44M derived: sum of 3 quarters · filed 2024-03-14 | $2.93M derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-03-31 | $550.00K 10-Q · filed 2023-05-11 | $1.08M derived: sum of 2 quarters · filed 2024-03-14 | $1.56M derived: sum of 3 quarters · filed 2024-03-14 | $1.89M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | $528.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $1.01M derived: sum of 2 quarters · filed 2024-03-14 | $1.34M derived: sum of 3 quarters · filed 2024-03-14 | $1.81M 10-K · filed 2024-03-14 |
| 2022-09-30 | $482.00K 10-Q · filed 2023-11-09 | $815.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.28M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $333.00K 10-Q · filed 2023-08-10 | $638.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $304.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $203.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |